Title : Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.

Pub. Date : 2020 Nov

PMID : 32603526






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Roxadustat induced transient elevations of endogenous erythropoietin that peaked between 7 and 14 hours after dosing and returned to baseline by 48 hours after dosing. roxadustat erythropoietin Homo sapiens